PRECISE Trial Rewrites the Patient Pathway

The results from the Prospective Randomized Trial of the Optimal Evaluation of Cardiac Symptoms and Revascularization (PRECISE) trial show evaluating patients with suspected CAD by applying advanced artificial intelligence (AI) to CCTA allows for more accurate non- invasive diagnosis, reduces unnecessary testing, and offers higher confidence in identifying patients needing treatment.

This panel of leading experts discusses insights from the PRECISE Trial 1-Year data, how the findings relate to the 2021 AHA/ACC Chest Pain Guidelines, and what the data tell us about different strategies for the evaluation and diagnosis of coronary artery disease.

Featuring Dr. Pamela S. Douglas, Dr. Maros Ferencik, and Dr. Gregg W. Stone

173961488 v2